Anne-Michelle Noone

Datos Biográficos

ID5534259
NOMBREAnne-Michelle Noone
NOMBRESAnne-Michelle
APELLIDONoone
FIRMANOONE A
AFILIACIONESNational Cancer Institute
VERIFICADONo
TOTAL DE OBRAS4
TOTAL DE CITAS0
TOTAL COMO AUTOR4
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2013
AÑO MÁS RECIENTE DE PUBLICACIÓN2025
ÍNDICE H0

  • Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (Seer) Treatment Data Use Agreement

    Yoon Duk Hong, Angela B Mariotto et al.ARTICLEMedical Care2025Referencias: 3

    INTRODUCTION: The Surveillance, Epidemiology, and End Results (SEER) Program collects data on the first course of cancer treatment, but no and unknown receipt of treatment cannot be distinguished for radiation therapy (RT) and chemotherapy. As part of the Data Use Agreement (DUA), users must acknowledge that they understand the data limitations and agree to include a description of the limitations in any analyses published using the data. The obj…

  • The Utility of Pathology Reports to Identify Persons With Cancer Recurrence

    Joan L Warren, Anne-Michelle Noone et al.ARTICLEMedical Care2022Referencias: 15

    BACKGROUND: Cancer recurrence is an important measure of the impact of cancer treatment. However, no population-based data on recurrence are available. Pathology reports could potentially identify cancer recurrences. Their utility to capture recurrences is unknown. OBJECTIVE: This analysis assesses the sensitivity of pathology reports to identify patients with cancer recurrence and the stage at recurrence. SUBJECTS: The study includes patients wi…

  • Comparison of Seer Treatment Data With Medicare Claims

    Open AccessAnne-Michelle Noone, Anne‐Michelle Noone et al.ARTICLEMedical Care2016Referencias: 19

    BACKGROUND: The population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other dat…

  • Physicians’ Beliefs About Breast Cancer Surveillance Testing are Consistent With Test Overuse

    Paul K J Han, Carrie N Klabunde et al.ARTICLEMedical Care2013Referencias: 42

    BACKGROUND: Overuse of surveillance testing for breast cancer survivors is an important problem but its extent and determinants are incompletely understood. The objectives of this study were to determine the extent to which physicians' breast cancer surveillance testing beliefs are consistent with test overuse, and to identify factors associated with these beliefs. METHODS: During 2009-2010, a cross-sectional survey of US medical oncologists and …